ClinicalTrials.gg
Not yet recruitingNCT07941362Updated Nov 17, 2026

177Lu-ACT319 in FAP Expressing Solid Tumors

A Phase 1/2 interventional study of 177Lu-ACT319 and 177Lu-ACT319 in FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC) and Biliary Tract Carcinoma (BTC), sponsored by Actithera INC.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Actithera INC. · Phase 1/2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
182
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last approximately 2 years.

A separate group of patients with other FAP expressing solid tumor types will be evaluated by PET/CT or SPECT/CT imaging for the intensity of target expression.

Read the detailed description

Part 1A evaluates escalating 177Lu-ACT319 doses in PDAC/BTC to estimate MTD and/or define RDE.

Part 1B is an open-label single-arm exploratory imaging sub-study in other FAP-expressing tumors.

Part 2A randomizes patients with PDAC 1:1 between Recommended Dose for Expansion (RDE and RDE-1 dose levels) to identify an optimized dose regimen/RP2D.

Part 2B may expand at the optimized dose in additional solid tumors selected from emerging data. FAP-positive disease is confirmed by PET/SPECT imaging. Treatment is IV administration every 6 weeks for up to 4 cycles, with up to 2 optional additional cycles based on benefits/safety.

02

Conditions studied

  • FAP-expressing Solid Tumors
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Biliary Tract Carcinoma (BTC)

Keywords

  • 177Lu-ACT319
  • fibroblast activation protein
  • FAP
  • radioligand therapy
  • radiopharmaceutical
  • PDAC
  • BTC
  • Sarcoma
  • colorectal cancer (CRC)
  • TNBC
  • HNSCC
  • NSCLC
  • SPECT/CT
  • PET/CT
  • Dosimetry
03

In context

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

This study's planned enrollment of 182 is above the median of 41 across 1,254 interventional studies indexed under Sarcoma.

Browse Sarcoma studies →

Lead sponsor

This is the only study on the registry with Actithera INC. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, age ≥ 18 years on the day of signing .
  • Histologically of confirmed advanced, unresectable and/or cancer. Participants must be to or not tolerant to existing therapies known to provide clinical benefits for their condition
  • At least one per v1.1 by investigator assessment.
  • FAPI PET/SPECT imaging positive.
  • Adequate organ and bone marrow function in the 7 days prior to treatment.
  • Patient (ECOG) performance status 0-2.
  • Anticipated of 6 months or higher in the opinion of the investigator.
  • Participants with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.

Exclusion criteria

Exclusion Criteria:

  • Known to the active substance, or to any of the of the 177Lu-ACT319.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled diabetes mellitus, symptomatic congestive heart failure, or unstable angina pectoris.
  • Participants who have not had resolution of all toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 - Active clinically significant cardiac disease
  • Any major surgery within 4 weeks before enrollment. - Pregnancy or breastfeeding. - Unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, study procedures, and requirements. - Known diagnosis of liver cirrhosis, systemic fibrotic condition such as pulmonary fibrosis, retroperitoneal fibrosis, etc.
  • Any concurrent systemic antineoplastic therapy for the underlying disease and/or other agents within a period which is ≤ 5 t1/2 or ≤ 2 weeks (whichever is longer) prior to the first injection of 177Lu-ACT319 (C1D1).
  • Treatment with any radiopharmaceutical within 6 weeks of Investigational medicinal product (IMP) or 10 half-lives, whatever is longer.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    177Lu-ACT319 dose escalation (Part 1A)

    In part 1A (dose escalation) - PDAC and BTC will be enrolled

    Drug: 177Lu-ACT319

  • Experimental
    FAP-targeted PET/CT or SPECT/CT imaging (Part 1B)

    In part 1B Exploratory imaging cohort to characterize FAP expression across multiple tumor types (different from PDAC/BTC) expressing FAP.

    Drug: [18F]-FAPI-74 for imaging · Drug: 177Lu-ACT319 for imaging

  • Experimental
    177Lu-ACT319 dose optimization and expansion (Part 2A)

    In part 2A; Patients with pancreatic ductal carcinoma will be enrolled for dose optimization and expansion.

    Drug: 177Lu-ACT319 at RDE · Drug: 177Lu-ACT319 at RDE-1

  • Experimental
    177Lu-ACT319 dose expansion (Part 2B)

    In 2B: patients with other solid tumors expressing FAP will be enrolled for dose expansion.

    Drug: 177Lu-ACT319 at RDE · Drug: 177Lu-ACT319 at RDE-1

Interventions

  • Drug177Lu-ACT319

    At Dose level 1

  • Drug177Lu-ACT319

    At Dose Level 2

  • Drug177Lu-ACT319

    At Dose Level 3

  • Drug177Lu-ACT319

    At Dose Level 4

  • Drug[18F]-FAPI-74 for imaging

    Low Dose \[18F\]-FAPI-74 for PET/CT imaging in Part 1B

  • Drug177Lu-ACT319 for imaging

    Low Dose 177Lu-ACT319 for imaging in Part 1B

  • Drug177Lu-ACT319 at RDE

    177Lu-ACT319 at Recommended Dose for Expansion

  • Drug177Lu-ACT319 at RDE-1

    177Lu-ACT319 at one level lower than at Recommended Dose for Expansion

06

What researchers measure

Primary outcomes

  1. Dose escalation (Part 1A)

    Incidence of Dose limiting Toxicities (DLTs.)

    Time frame: First 42 days of Cycle 1

  2. Imaging/Dosimetry Sub-study (Part 1B)

    Ratio of Standardized Uptake Value (SUV) to reference region SUV measured using PET/SPECT imaging.

    Time frame: 2 days post drug administration

  3. Dose optimization and expansion (Part 2A/2B)

    Objective Response Rate (ORR) defined as the percentage of participants who achieve a PR or CR to therapy locally assessed by the investigator as measured by RECIST v1.1.

    Time frame: Up to 12 months after the last treatment.

  4. Dose escalation (Part 1A)

    Type, Frequency and severity of Adverse events and SAEs in all patients who received at least one dose of the study drug.

    Time frame: Up to 24 months from the first treatment cycle administration.

  5. Imaging/Dosimetry Sub-study (Part 1B)

    Type, frequency and severity of AEs and SAEs.

    Time frame: Up to 8 days.

  6. Dose escalation (Part 1A)

    Frequency and duration of dose delays, dose interruptions, and dose reductions.

    Time frame: Up to 24 months from the first treatment cycle administration.

  7. Vital Signs: Change from baseline in systolic blood pressure (Part 1B)

    Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 8 days.

  8. Vital Signs: Change from baseline in diastolic blood pressure (Part 1B)

    Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 8 days.

  9. Vital Signs: Change from baseline in pulse rate (Part 1B)

    Change from baseline in pulse rate, measured in beats per minute.

    Time frame: Up to 8 days.

  10. Vital Signs: Change from baseline in respiratory rate (Part 1B)

    Change from baseline in respiratory rate, measured in breaths per minute.

    Time frame: Up to 8 days.

  11. Vital Signs: Change from baseline in body temperature (Part 1B)

    Change from baseline in body temperature, measured in degrees Celsius.

    Time frame: Up to 8 days.

  12. ECGs: Change from baseline in ECG heart rate (Part 1B)

    Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

    Time frame: Up to 8 days.

  13. ECGs: Change from baseline in ECG PR interval (Part 1B)

    Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 8 days.

  14. ECGs: Change from baseline in ECG QRS duration (Part 1B)

    Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 8 days.

  15. ECGs: Change from baseline in ECG QT interval (Part 1B)

    Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 8 days.

  16. Imaging sub-study (Part 1B): Number of participants with clinically significant laboratory abnormalities

    Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or other applicable safety laboratory test as assessed by the investigator. Each participant is counted once, regardless of the number of qualifying abnormalities or assessment visits.

    Time frame: Up to 8 days.

  17. ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1B)

    Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds

    Time frame: Up to 8 days.

  18. Dose escalation (Part 1A)

    MTD and/or RDE as determined by the BOIN dose-escalation algorithm based on observed DLT rates.

    Time frame: First 42 days of Cycle 1

  19. Vital Signs: Change from baseline in systolic blood pressure (Part 1A, 2A, 2B)

    Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 24 months from the first treatment cycle administration.

  20. Vital Signs: Change from baseline in diastolic blood pressure (Part 1A, 2A, 2B)

    Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 24 months from the first treatment cycle administration.

  21. Vital Signs: Change from baseline in pulse rate (Part 1A, 2A, 2B)

    Change from baseline in pulse rate, measured in beats per minute.

    Time frame: Up to 24 months from the first treatment cycle administration.

  22. Vital Signs: Change from baseline in respiratory rate (Part 1A, 2A, 2B)

    Change from baseline in respiratory rate, measured in breaths per minute.

    Time frame: Up to 24 months from the first treatment cycle administration.

  23. Vital Signs: Change from baseline in body temperature (Part 1A, 2A, 2B)

    Change from baseline in body temperature, measured in degrees Celsius.

    Time frame: Up to 24 months from the first treatment cycle administration.

  24. ECGs: Change from baseline in ECG heart rate (Part 1A, 2A, 2B)

    Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

    Time frame: Up to 24 months from the first treatment cycle administration.

  25. ECGs: Change from baseline in ECG PR interval (Part 1A, 2A, 2B)

    Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months from the first treatment cycle administration.

  26. ECGs: Change from baseline in ECG QRS duration (Part 1A, 2A, 2B)

    Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months from the first treatment cycle administration.

  27. ECGs: Change from baseline in ECG QT interval (Part 1A, 2A, 2B)

    Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months from the first treatment cycle administration.

  28. ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1A, 2A, 2B)

    Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months from the first treatment cycle administration.

  29. ECOG: Change from baseline in ECOG performance status (Part 1A, 2A, 2B)

    Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score. Scores range from 0 to 5, with higher scores indicating worse performance status.

    Time frame: Up to 24 months from the first treatment cycle administration.

  30. Dose Escalation (Part 1A): Number of participants with clinically significant laboratory abnormalities

    Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis tests, as assessed by the investigator. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits.

    Time frame: Up to 24 months from the first treatment cycle administration

  31. Dose optimization and expansion (Part 2A)

    Selection of the dose regimen with the most favorable overall benefit-risk profile among the dose levels evaluated in Part 2A (RP2D).

    Time frame: Up to 24 months.

Secondary outcomes

  1. Dose escalation (Part 1A): Maximum observed blood concentration (Cmax) of total ACT319.

    Maximum observed blood concentration (Cmax) of total ACT319 in blood derived from the blood concentration time data

    Time frame: Cycle 1: up to Day 8 post-dose.

  2. Dose escalation (Part 1A): Time of the peak of blood concentration (Tmax) of total ACT319.

    Time after administration to the maximum observed concentration of total ACT319 in blood.

    Time frame: Cycle 1: up to Day 8 post-dose.

  3. Dose escalation (Part 1A): Blood concentration plotted against time (AUC) of total ACT319.

    Area under the total ACT319 blood concentration time curve

    Time frame: Cycle 1: up to Day 8 post-dose.

  4. Dose escalation (Part 1A): Blood Elimination time for ACT319 (t1/2).

    Terminal elimination half-life of total ACT319 derived from the blood concentration time data.

    Time frame: Cycle 1: up to Day 8 post-dose.

  5. Dose escalation (Part 1A): Maximum observed blood radioactivity concentration (Cmax) of 177Lu-ACT319.

    Maximum observed radioactivity concentration in blood following administration of 177Lu-ACT319

    Time frame: Cycle 1: Up to Day 8 post-dose.

  6. Dose escalation (Part 1A): Time to maximum observed blood radioactivity concentration (Tmax) of 177Lu-ACT319.

    Time after administration of 177Lu-ACT319 to the maximum observed radioactivity concentration in blood

    Time frame: Cycle 1: up to Day 8 post-dose.

  7. Dose escalation (Part 1A): Area under the blood radioactivity concentration curve (AUC) of total 177Lu-ACT319.

    Area under the blood radioactivity concentration time curve following administration of 177Lu-ACT319.

    Time frame: Cycle 1: up to Day 8 post-dose.

  8. Dose escalation (Part 1A): Elimination half-life (t1/2) of 177Lu-ACT319 in blood

    Elimination half-life derived from blood radioactivity measurements following administration of 177Lu-ACT319.

    Time frame: Cycle 1: up to Day 8 post-dose.

  9. Dose escalation (Part 1A): Cumulative amount of 177Lu-ACT319 excreted in urine (Ae).

    Culminative radioactivity excreted in urine following administration of 177Lu-ACT319 over the planned urine collection interval.

    Time frame: Cycle 1: up to Day 8 post-dose.

  10. Dose escalation (Part 1A): Cumulative percentage of 177Lu-ACT319 excreted in urine (Ae%).

    Culminative radioactivity excreted in urine expressed as a percentage of administered radioactivity over the planned urine collection interval.

    Time frame: Cycle 1: up to Day 8 post-dose.

  11. Dose escalation (Part 1A): Renal clearance (CLR) of 177Lu-ACT319.

    Renal Clearance derived from urinary radioactivity excretion and corresponding blood radioactivity exposure following administration of 177Lu-ACT319

    Time frame: Cycle 1: up to Day 8 post-dose.

  12. Dose escalation (Part 1A)

    Radioactivity uptake in normal organs and tumor lesions.

    Time frame: Cycle 1: up to Day 8 post-dose.

  13. Dose escalation (Part 1A)

    Tumor-to-background ratio defined as the ratio of the lesion SUV over the reference region SUV.

    Time frame: Cycle 1: Up to Day 8

  14. Dose optimization and expansion (Part 2A and 2B)

    Type, frequency and severity of AEs and SAEs using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: Up to 24 months from the first treatment cycle administration.

  15. Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in systolic blood pressure

    Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 24 months from the first treatment cycle administration

  16. Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in diastolic blood pressure

    Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg).

    Time frame: Up to 24 months the first treatment cycle administration.

  17. Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in pulse rate.

    Change from baseline in pulse rate, measured in beats per minute.

    Time frame: Up to 24 months the first treatment cycle administration.

  18. Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in respiratory rate

    Change from baseline in respiratory rate, measured in breaths per minute.

    Time frame: Up to 24 months the first treatment cycle administration.

  19. Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in body temperature

    Change from baseline in body temperature, measured in degrees Celsius.

    Time frame: Up to 24 months the first treatment cycle administration.

  20. ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG heart rate

    Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute.

    Time frame: Up to 24 months the first treatment cycle administration.

  21. ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG PR interval,

    Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months the first treatment cycle administration.

  22. ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QRS duration.

    Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months the first treatment cycle administration.

  23. ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QT interval.

    Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months the first treatment cycle administration.

  24. ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in Fridericia-corrected QT interval (QTcF).

    Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds.

    Time frame: Up to 24 months the first treatment cycle administration.

  25. ECOGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECOG performance status

    Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score.

    Time frame: Up to 24 months the first treatment cycle administration.

  26. Dose optimization and expansion (Parts 2A and 2B): Number of participants with clinically significant laboratory abnormalities.

    Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits.

    Time frame: Up to 24 months the first treatment cycle administration.

  27. Dose optimization and expansion (Part 2A and 2B)

    Frequency and duration of dose delays, dose interruptions, and dose reductions.

    Time frame: Up to 24 months from the first treatment cycle administration.

  28. Dose optimization and expansion (Part 2A and 2B)

    Progression Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause.

    Time frame: up to 12 months after last cycle.

  29. Dose optimization and expansion (Part 2A and 2B)

    Overall Survivor (OS) defined as the time from C1D1 to death from any cause

    Time frame: Up to 24 months from the first treatment cycle administration.

  30. Dose optimization and expansion (Part 2A and 2B)

    Disease control Rate (DCR) defined as the percentage of participants who have achieved CR, PR, or SD.

    Time frame: Up to 12 months.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2029, 33 months later.

Of 44 industry-sponsored phase 1/2 interventional studies under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 33 months is below that.

Counting every sponsor, half of 101 studies reached it within 62 months; a quarter within 45 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Nov 17, 2026
StartEst.
Oct 25, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Nov 2, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941362
Lead sponsor
Actithera INC.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Oct 25, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Nov 2, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Head of Clinical Operations
Contact
info@actithera.com
+1-617-780-8045

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion